SEC Form 4 · accession 0001209191-16-131914
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Julian S Gangolli
Director
Period of report
Jul 1, 2016
Accepted (ET)
Jul 6, 2016 · 7:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $13.62 | Jul 1, 2016 | A | 18,000 | A | — | Jun 30, 2026 | Common Stock | 18,000 | 18,000 | D |
Explanation of responses
- F1The shares subject to the stock option shall vest on the one-year anniversary of the date of grant subject to Mr. Gangolli's Continuous Service, as defined in the Issuer's 2014 Equity Incentive Plan, through such vesting date.